Skip to main content

Author: The Wistar Institute

Global Voices for HIV Advocacy and Cure Research Come Together at Wistar’s 26th Annual Jonathan Lax Lecture

This year, The Wistar Institute hosted the Annual Jonathan Lax Memorial Award Lecture virtually, bringing together HIV scientists and activists on a global stage. Celebrating 26 years of continuous HIV research collaboration, the event was streamed on June 28, 2022, and saw attendees from North and South America, Europe, Africa, and Asia. The event opened with a music video by Moses “Supercharger” Nsubuga, HIV Outreach and HIV Cure Research Advocate and musician from Uganda and the Stigmaless Band performing their song “Optimistic”. It set a positive and engaging tone, reminding everyone that researchers and activists are working toward a common goal of HIV cures that prevent, control, and treat the virus.

The keynote speaker delivering the Lax Lecture was Mike McCune, M.D., Ph.D., head of the HIV Frontiers Initiative of the Bill & Melinda Gates Foundation, who emphasized the scientific progress toward curative interventions for HIV for all parts of the world. He highlighted efforts toward the development of gene therapies and “single shot” vaccine candidates and looking forward to clinical trials.

McCune expanded on his view of the ideal HIV cure. It would be available in an outpatient clinic; it would be given in one shot—like a vaccine—and durable for three years, yet a lifetime would be ideal; it must prevent or control infection but doesn’t require complete eradication; and it would be affordable for underdeveloped nations/low-income nations at $1000-2000 per administration. Also, McCune mentioned creating an affordable home testing kit, similar to COVID-19 test kits, for people to monitor if the disease is under control.

McCune shared, “We need to have a long-term vision and we need to have steps along the way that show we’re moving towards it.”

The event also hosted a panel centered around the question “What does an HIV cure mean to you?”. The global community discussion included Moses “Supercharger” from Uganda; Philister Adhiambo, Community Liaison Officer and HIV Cure Advocate from Kenya; and Michael Louella, Community Engagement Project Manager of the defeatHIV collaborative in the U.S. They all agreed that research can move forward if it prioritizes the community. Their strong perpectives came from the realities they see every day in their communities: participation in cure-directed studies, of being female with HIV/AIDS, living with HIV/AIDS in low- and middle-income countries outside the U.S., remaining on antiretrovirals for decades not knowing the toll it takes on their bodies, and stigmatized people that lost opportunities because they were HIV positive.

“26 years ago, we set out to make a difference in HIV/AIDS treatment strategies through the most cutting-edge research, done shoulder-to-shoulder with clinicians, advocates, and people living with HIV/AIDS in Philadelphia,” said Luis J. Montaner, D.V.M., D.Phil., Herbert Kean, M.D., Family Professor, leader of the HIV Research Program at The Wistar Institute, and co-principal investigator of the BEAT-HIV Delaney Collaboratory. “Our program has now grown beyond the region and country to gain a network across the globe. Our mission hasn’t changed, but we have grown into a global center to report the most groundbreaking HIV cure research together with community input.”

McCune stated, “Now is the time to move forward. Solving these challenges is not going to happen overnight, but it’s starting now.”

Taking on Cancer

Philadelphia Business Journal senior health reporter John George hosted Taking on Cancer, a two-panel discussion that kicked off with perspectives from local research leaders at the helm of world-class research institutes and health care systems. It was followed by the innovative go-getters behind health care startups in the region. The intimate event took place in the high ceiling, music venue City Winery in Philadelphia’s Center City.

Leaders sat shoulder to shoulder to discuss the challenges and changes to cancer research and patient care. The first panel gave perspectives on what the future holds for the region and included Dr. Dario Altieri, Wistar Institute president & CEO, director of the Ellen and Ronald Caplan Caner Center, and the Robert and Penny Distinguished Professor; Dr. Generosa Grana, MD Anderson Cancer Center at Cooper director; Dr. Jonathan Chernoff, Fox Chase Cancer Center director; Dr. Andy Chapman, Jefferson Health’s Sidney Kimmel Cancer Center director; and Dr. Robert Vonderheide, University of Pennsylvania’s Abramson Cancer Center director.

Dr. Altieri represented the panel’s lone basic cancer research center and brought a high-level drug discovery perspective to what John George coined Philadelphia—an “epicenter for cancer research”. Dr. Altieri stated, “We’ve gotten better at public-private partnerships, and we’ve greatly improved the dynamics related to drug discovery and development. We’ve been exploring more and are doing a better job advancing promising new assets, so we are seeing a higher number of success stories.”

The other leaders, representing comprehensive cancer centers that treat patients and conduct research, felt the same – that the last 20 years of cancer research has been a sort of science revolution in our understanding of how genes act together and the hopes of altering or editing them, how to identify and predict cancer risk, and how to treat immune system pathways that were once thought undruggable with emerging drug candidates. In the process, Philadelphia has become central to cell and gene therapy and referenced as “Cellicon Valley”. The region now also supports a teeming cell and gene therapy ecosystem backed by a workforce that understands bioprocessing this “living drug”.

Together, the panel agreed that Philadelphia is poised to be a leading city in the battle against cancer—all due to the innovation of academic institutes coupled with innovative business investment and supporting infrastructure, and the ability to provide delocalized, multidisciplinary care to cancer patients.

As we continue shaping and building this life science ecosystem, Dr. Altieri remarked on the day-to-day challenges of cancer research and what’s to come. “At times, things may not seem to move fast enough, and our work seems incremental, taking only small steps forward. However even those count, as we move away from dogma and assumptions and from the mindset that there are undruggable targets. Discovery through innovation will become more adventurous.”

Jonathan Lax Memorial Award Lecture Streams Globally

PHILADELPHIA—(June 23, 2022)—The Wistar Institute, a biomedical research leader in cancer, immunology, and infectious disease, announces that for the first time it will globally stream its 26th Annual Jonathan Lax Memorial Award Lecture, celebrating 26 years of providing state-of-research updates to the community, on Tuesday, June 28 from 9:30 to 11:00 a.m. EST. From across the globe, scientists, activists, advocates, and community leaders will come together online to share scientific strides and community progress on the global HIV cure agenda front.

Mike McCune, M.D., Ph.D., head of the HIV Frontiers Initiative and Biotechnology Accelerator Program of the Bill & Melinda Gates Foundation, will deliver the 26th Annual Jonathan Lax Memorial Award Lecture at this virtual, Wistar-hosted event. McCune’s lecture will highlight the ongoing efforts to reach an HIV cure that is accessible to every community across the world. This year’s global health theme will be echoed by guest speakers including Luis J. Montaner, D.V.M., D.Phil., Herbert Kean, M.D., Family Endowed Chair Professor, leader of the HIV Research Program at The Wistar Institute, and co-principal investigator of the BEAT-HIV Delaney Collaboratory; Moses “Supercharger” Nsubuga, HIV advocate-musician-radio host; Jane Shull, chief executive officer of Philadelphia FIGHT; and others.

“26 years ago, we set out to provide clinicians, advocates, and people living with HIV/AIDS in Philadelphia a state-of-research update by bringing the most important developments affecting HIV/AIDS treatment strategies or cure-directed efforts,” said Montaner. “This year we are pleased to grow our community beyond the region and country and gain a network across the Americas, Europe, Africa, and Asia. Our mission hasn’t changed, but we have grown into a global center for the most groundbreaking HIV cure research.”

“To move scientific innovation forward for all humanity, we need greater inclusion and participation in the research process and collaborations of all kinds—across people, partnerships, sectors, countries, and beyond. These are a hallmark of Dr. Montaner’s HIV research program,” said Dario C. Altieri, M.D., Wistar president and CEO, director of the Ellen and Ronald Caplan Cancer Center and Robert and Penny Fox Distinguished Professor. “That collaborative might is embodied in the BEAT-HIV Martin Delaney Collaboratory. True impact is felt through their ability to articulate HIV cure goals to communities on an international scale, thereby bringing greater awareness to the goals of HIV cure research on the worldwide stage.”

The 2022 lecture is free and open to a global audience. Register here.

The Jonathan Lax Memorial Award Lecture was established by The Wistar Institute and Philadelphia FIGHT after Mr. Lax’s death to honor his legacy by bringing distinguished speakers to a lay audience. Past speakers have included luminaries in the HIV/AIDS field such as Nobel Laureate Françoise Barré-Sinoussi, Ph.D., emeritus professor at the Institut Pasteur; David D. Ho, M.D., professor of microbiology and immunology at Columbia University; and Anthony S. Fauci, M.D., director of the National Institute of Allergy and Infectious Diseases.

The Lecture honors Jonathan Lax, President of the Board of Philadelphia FIGHT, who died from complications due to AIDS in 1996. A successful businessman, Mr. Lax was a leading advocate for bringing information directly to people living with HIV and their families. He devoted personal resources throughout his life to helping people learn how to make decisions that would affect their health care as a person living with HIV. In the pre-internet era, Mr. Lax helped FIGHT sponsor many public forums to assure that people living with HIV/AIDS had access to up-to-date information delivered by recognized specialists.

The 2022 Jonathan Lax Memorial Award Lecture global sponsors are: Canadian HIV Cure Enterprise (CANCure), EU2Cure, Federation of African Immunological Societies (FAIS), Global Gene Therapy Initiative (GGTI), HIV Cure Africa Acceleration Partnership (HCAAP), Indian Immunology Society (IIS), Jawaharlal Nehru Centre for Advanced Scientific Research (JNCASR), Joint Adherent Brothers and Sisters Against AIDS (JABASA), Penn CFAR, Philadelphia FIGHT, Philadelphia Foundation, Sociedad Argentina de Infectología (SADI), and The Wistar Institute.

Editor’s Note: All awardees will receive the Jonathan Lax Memorial Award virtually. For more information or to cover the event, contact Darien Sutton at 215-870-2048 or dsutton@wistar.org.

###

The Wistar Institute is an international leader in biomedical research with special expertise in cancer, immunology, infectious diseases, and vaccine development. Founded in 1892 as the first independent nonprofit biomedical research institute in the United States, Wistar has held the prestigious Cancer Center designation from the National Cancer Institute since 1972. The Institute works actively to ensure that research advances move from the laboratory to the clinic as quickly as possible. wistar.org

BEAT-HIV Delaney Collaboratory is part of an international consortium of more than 80 top HIV researchers from academia, industry, government, and nonprofit sectors working toward an HIV cure. The Collaboratory is leading three advanced trials to define effective ways to combine immunotherapy regimes towards a cure. BEAT-HIV.org

Philadelphia FIGHT is a Federally Qualified Health Center (FQHC) offering HIV treatment and primary care to people living with HIV/AIDS and those at high risk, as well as community education and outreach programs on HIV, Hepatitis, and other topics impacting public health. During the COVID-19 pandemic, FIGHT has provided no barrier, walk-up COVID testing to over 19,000 people in low-income neighborhoods of Philadelphia, and partnered with ten community based organizations to bring COVID vaccines to these communities.

Wistar Scientists Identify Novel Therapeutic Approach to Re-activate Immune Response Against Tumors

PHILADELPHIA — (June 21, 2022) — Due to the development of resistance to chemotherapy and recurring tumors, patients with ovarian cancer often have low survival rates. Therefore, new therapeutic options such as targeted therapy that boosts anti-tumor immunity are needed to improve ovarian cancer treatment efficacy and patient survival.

In a research paper published today in Cancer Immunology Research, Rugang Zhang, Ph.D., deputy director of the Ellen and Ronald Caplan Cancer Center, Christopher M. Davis Endowed Professor, and program leader of the Immunology, Microenvironment & Metastasis Program, at The Wistar Institute, and his team identified that inhibiting therapeutic target KDM5A boosts a person’s immune response to tumors.

“Understanding the basic mechanism guiding the infiltration of tumor-killing immune cells into the tumor microenvironment is key to leveraging the power of immune system to fight against cancer,” states Zhang.

Sergey Karakashev, a recent postdoctoral researcher in the Zhang lab and co-author on the paper, elaborates. “Tumor infiltration with immune cells is one of the best predictors for survival and for better prognosis for ovarian cancer patients. We were interested in finding a way to increase tumor infiltration with immune cells.” he says.

KDM5A is an oncogene that is often amplified in epithelial ovarian cancer and is known to repress multiple genes that are involved in tumor suppression. In this study, the scientists reveal the mechanism underpinning how KDM5A regulates immune cell infiltration and attack of tumors – by inhibiting genes involved in the antigen processing and presentation pathway. This biological pathway recognizes tumor cells and activates the immune system to invade and ultimately kill them.

“Tumor cells find a way to downregulate this antigen presenting pathway, and by doing so, they evade immune surveillance. One of the main questions for this paper was ‘How we can restore the function of the antigen presentation pathway to promote immune infiltration and immune cell activation?’” Karakashev explains.

To do this, the team conducted both in vitro and in vivo studies. In vitro, the team found that genes involved in the antigen presentation pathway were indeed upregulated when they knocked out KDM5A and saw the same results when they used a KDM5A specific inhibitor. For in vivo studies using mice and mouse ovarian cancer cells, the in vitro results were validated. According to the paper, KDM5A inhibition reduced tumor burden and improved survival of the tumor bearing mouse model. The in vivo experiments saw an increase in the presence of CD8 + cells which are the effector killing cells of the immune system. Additionally, more of these cells were activated, which means they were able to act against tumors in mice.

“This is a very early study,” Karakashev says, “We want to try more clinically relevant inhibitors of KDM5A and more models to increase the translatability of our findings to the clinic. Another interesting future direction would be to study KDM5A in other cancers as well.” The scientists hope that this paper will inspire more research into other epigenetic factors that regulate immune related pathways and see potential in combining this therapeutic target with other immune therapies to be effective against ovarian cancer.

Zhang says, “Our findings provide a scientific framework to target KDM5A to overcome immune evasion employed by cancer cells. In addition to ovarian cancer, the pathway appears to be broadly applicable to many cancer types. Thus, we believe the findings are broadly applicable and may have far-reaching implications in developing cancer immunotherapy.”

Co-authors: Heng Liu, Jianhuang Lin, Wei Zhou, Zhongping Dai, Andrew Kossenkov, Sergey Karakashev of The Wistar Institute; Renyta Moses, Ronny Drapkin from The University of Pennsylvania; Benjamin G. Bitler from The University of Colorado.

Work supported by: National Institutes of Health grants (R01CA202919, R01CA239128, and P50CA228991 to R. Zhang; K99CA241395 to S. Karakashev), the U.S. Department of Defense (OC180109 and OC190181 to R. Zhang), The Honorable Tina Brozman Foundation for Ovarian Cancer Research and The Tina Brozman Ovarian Cancer Research Consortium 2.0 (to R. Zhang), and Ovarian Cancer Research Alliance (Collaborative Research Development Grant #596552 to R. Zhang and the Ann and Sol Schreiber Mentored Investigator Award to W. Zhou #812528).

Publication Information: KDM5A inhibits anti-tumor immune response through downregulation of antigen presentation pathway in ovarian cancer. Cancer Immunology Research, 2022. Online publication.

###

The Wistar Institute is an international leader in biomedical research with special expertise in cancer research and vaccine development. Founded in 1892 as the first independent nonprofit biomedical research institute in the United States, Wistar has held the prestigious Cancer Center designation from the National Cancer Institute since 1972. The Institute works actively to ensure that research advances move from the laboratory to the clinic as quickly as possible. wistar.org.

Wistar Institute Launches Bold Science // Global Impact Capital Campaign to Rechart the Future of Human Health

PHILADELPHIA — (June 16, 2022) —The Wistar Institute, an international biomedical research leader in cancer, immunology and infectious disease, announces its Bold Science // Global Impact Capital Campaign to support a five-year plan that sets out Wistar’s roadmap for accelerated progress to drive breakthroughs in biomedical science and technology and educate and train the next generation of innovators.

“A once-in-a-century pandemic taught us the critical need to be nimble—to have the scientific freedom, capacity, and agility to rechart the course of human health,” said Dario Altieri, M.D., Wistar president and CEO, Ellen and Ronald Caplan Cancer Center director, and Robert and Penny Fox Distinguished Professor. “That’s why we’re taking bold action now with an Institute-wide commitment to push forward and deliver purposeful, transformative impacts on health and life science. The ambitious goals we’ve set for The Wistar Institute could not be achieved without the committed participation of our science collaborators and the Board of Trustees, who are dedicated to advancing the vision.”

The Institute’s ambitious Capital Campaign ensures that Wistar’s vision of Bold Science // Global Impact becomes a reality. Chaired by Ronald Caplan, president of PMC Property group and a long-term member of Wistar’s Board of Trustees, the successful campaign has already raised nearly 60 percent of its $75 million goal, including an anonymous $20 million gift, since the initiation of its silent phase in January.

“In my 20 years serving Wistar’s Board, I’ve witnessed the organization’s tremendous growth as an engine of indispensable research, and now it’s poised for even greater scientific leadership,” said Richard M. Horowitz, chairman and CEO of RAF Industries, Inc., and chair of Wistar’s Board of Trustees. “My day-to-day work is focused on making investments, and I believe that being able to influence the future of society’s health through trailblazing science is one of the greatest investments you can make.”

Philanthropic support of the Bold Science // Global Impact Capital Campaign will fund the expansion of the Ellen and Ronald Caplan Cancer Center and the Vaccine & Immunotherapy Center as well as the creation of the Center for Advanced Therapeutics and the Hubert J.P. Schoemaker Education and Training Center.

The recently renamed Ellen and Ronald Caplan Cancer Center will help transform the prevention and treatment of cancer by advancing fundamental and translational research into next-generation therapeutics. This will involve expansive recruitment of new leaders in cancer research focusing on key areas of treatment resistance, metabolic and cellular reprogramming, cancer systems biology, and personalized anticancer strategies.

The Vaccine & Immunotherapy Center will strengthen the Institute’s capacity to support pandemic preparedness as well as expand pioneering research to accelerate advances in drug development – including innovative platforms for novel drug candidates to halt disease resistance, advance diagnostics, and accelerate discovery of personalized treatment strategies.

The creation of the Center for Advanced Therapeutics, Wistar’s latest interdisciplinary endeavor, will come to fruition as part of the five-year strategic plan beginning this fall. The Center will integrate computational biology, artificial intelligence, and structural biology with next generation sequencing technologies and groundbreaking immunotherapy research. The Center aims to tailor medicines with the potential to radically transform the treatment of some of the most dangerous and widespread diseases by harnessing the immune system in truly novel ways.

The Institute will also create the Hubert J.P. Schoemaker Education and Training Center, whose mission is to broaden and enhance education and mentorship opportunities for current and aspiring researchers. Distinct programs designed for high school, pre-apprenticeship, and apprenticeship education as well as graduate and postdoctoral training will create career opportunities and foster a diverse life science talent pipeline. Within the new Center, the Institute’s flagship training program will be renamed the Fox Biomedical Research Technician Apprenticeship program and undergo expansion of students and partners across the state.

View the campaign video below.

###

The Wistar Institute is an international leader in biomedical research with special expertise in cancer research and vaccine development. Founded in 1892 as the first independent nonprofit biomedical research institute in the United States, Wistar has held the prestigious Cancer Center designation from the National Cancer Institute since 1972. The Institute works actively to ensure that research advances move from the laboratory to the clinic as quickly as possible. wistar.org.

Wistar’s Dr. Amelia Escolano Named 2022 Pew Scholar

PHILADELPHIA — (JUNE 14, 2022) — The National Advisory Committee of the Pew Scholars Program in the Biomedical Sciences, has chosen Amelia Escolano, Ph.D., Assistant Professor in The Wistar Institute’s Vaccine & Immunotherapy Center, to join their 2022 cohort of Scholars. The honor provides Escolano with a grant of $300,000 over four years, starting in August 2022. A signature piece of the award provides support for Escolano to attend the annual five-day meeting with fellow Scholars to bolster a collaborative research community over the duration of the award.

Escolano completed her education and scientific training across several countries – Spain, Finland, and the United States. Recruited to Wistar in 2021, she has since made great strides in her work on new vaccination approaches for highly mutating viruses like HIV-1. The Pew Scholar funding will support her project to develop innovative approaches to investigate the immune response to vaccination that will be the basis to eventually design universal vaccines against mutating viruses – a pressing global health challenge.

“I want to thank The Pew Charitable Trusts (Pew) for this tremendous honor and for their support of my research. I look forward to participating in the annual meeting and engaging with the incredible community of Scholars, current and past.” expresses Escolano.

Pew Scholars are chosen from a pool of highly talented, early career investigators nominated by leading scientific universities and institutions around the United States. Pew supports these Scholars with research funding as they tackle unanswered biomedical questions and improve scientific innovation. The award also opens the door to a collaborative network of scientists and mentorship from leading scientific minds from the program’s national advisory committee.

“We are extremely proud of Amelia and this outstanding recognition in one of the most prestigious and competitive venues ever—she is one of 22 Scholars across the nation selected for this prestigious award,” said Dario C. Altieri, M.D., Wistar president & CEO, director of the Ellen and Ronald Caplan Cancer Center, and the Robert and Penny Fox Distinguished Professor. “The combination of bold ideas, innovative science, and commitment to improve human health is at the core of both The Wistar Institute and the Pew Scholars program: Amelia is an exceptional candidate who embodies those values as she tackles some of the most impactful, transformative research questions in immunology and infectious diseases.

The views expressed are those of the author(s) and do not necessarily reflect the views of The Pew Charitable Trusts.

###

The Wistar Institute is an international leader in biomedical research with special expertise in cancer research and vaccine development. Founded in 1892 as the first independent nonprofit biomedical research institute in the United States, Wistar has held the prestigious Cancer Center designation from the National Cancer Institute since 1972. The Institute works actively to ensure that research advances move from the laboratory to the clinic as quickly as possible. wistar.org.

Pennsylvania Department of Labor and Industry and Legislator Tour Wistar

The Wistar Institute was awarded a PAsmart grant of $650,000 from the Pennsylvania Department of Labor & Industry to expand education and training programs further across the region and create additional opportunities for more students to prepare for careers in the growing life science industry.

On June 9, 2022, Pennsylvania Department of Labor and Industry Secretary Jennifer Berrier and State Senator Vincent Hughes toured the Institute to learn more about how this investment into Wistar helps bolster the Pennsylvania workforce. In addition to hearing about the various ongoing research projects, Berrier and Hughes met some of the students who are participating in the Biomedical Technician Training (BTT) Program and summer internships following the Biomedical Research Methods course offered through a collaboration between Wistar and Cheyney University.

On the tour, the visitors saw Wistar’s Training Laboratory where students engage in hands-on training in practical laboratory skills to prepare them for working in the life sciences. They heard from Maureen Murphy, Ph.D., Ira Brind Professor and Program Leader, Molecular & Cellular Oncogenesis Program, Ellen and Ronald Caplan Cancer Center, on how her research on cancer genetics in people of African descent forms the basis for coursework in Wistar’s flagship pre-apprenticeship Biomedical Technician Training Program and the Biomedical Research Methods course. The tour included visits to the Altieri Lab, Montaner Lab, and Ertl Lab to discuss Wistar’s cancer research, HIV cure efforts, and infectious disease projects and students from the BTT Program and Cheyney University spoke about their experiences.

In closing with a roundtable conversation with President and CEO Dario Altieri, M.D., and Dean of Biomedical Studies Kristy Shuda McGuire, Ph.D., the secretary and senator discussed the importance of diverse talent pipelines, providing career growth and opportunity to underserved populations, and Wistar’s integral role in forwarding these goals.

“With our newly awarded PAsmart grant, we are on track to expand our pre-apprenticeship and apprenticeship programs in southeastern PA and create additional programs, offered to more students, and including more employers,” said Dr. Kristy Shuda McGuire. “In this growing Pennsylvania life-science industry, the talent pipeline is vital for cultivating the next generation of leaders in biomedical science.”

Wistar Grows its Collaborative Network Offering Internships in Biotechnology and Life Sciences

Wistar’s Biomedical Technician Training (BTT) Program was developed with the commitment to provide its students hands-on training and industry experience not traditionally delivered in academic classrooms.

The Wistar Institute’s training program has a rewarding history with many innovative biotechnology companies. Industry leader Integral Molecular has been involved with the BTT Program for over 10 years and has trained 15 BTT students and two apprentices – both of whom are now full-time employees. “Wistar’s educational programs help fill a critical need for lab technicians in the greater Philadelphia area to keep up with the growth in cell and gene therapy. The students come to us with a solid foundation of laboratory skills due to the excellent training through the BTT Program.” shares Sharon Willis, Ph.D., Vice President of Sales and Customer Relations at Integral Molecular.

Lake Paul, Ph.D., President and founder of industry collaborator BioAnalysis LLC, states “The Wistar Institute is an invaluable resource and partner of BioAnalysis, LLC, and we especially treasure the time we spend working with our Wistar interns. Enabling the life science interns with practical knowledge is paramount to our mission at BioAnalysis, LLC, which includes creating opportunities in underrepresented populations in the field of biophysics and analytical chemistry.”

The Institute continues to grow its education and workforce development opportunities – specifically regarding the BTT Program – with its newest biotechnology industry collaborator Chimeron Bio who is mentoring two Wistar BTT Program students this summer in nanoparticle production, quality control, and assessment – a first for the biotech company. This industry experience allows participants to learn how a biotech company operates, and engage with industry experts in a supportive learning environment.

For Lois Tolvinski, a graduate of Wistar’s BTT Program and Chimeron internship mentor, her career has come full circle, stating “The BTT Program really built that foundation for me to enter a career in the lab. I wouldn’t be here if it weren’t for the program and I’m very excited to be able to provide an opportunity for the next generation of BTT students to be able to learn what it’s like to work in an industry setting.”

Chimeron Bio Founders, Dr. Jolly Mazumdar, Ph.D., MBA, and Dr. Thimmaiah Chendrimada, Ph.D., MBA, issued a joint statement – “Our internship mission aligns very well with Wistar’s philosophy of training candidates, creating opportunities in a practical and engaging work environment, advancing quality research, and being a quality player in the Philadelphia research ecosystem. We have firsthand experience with graduates of the Wistar’s BTT Program via Lois Tolvinski, Manager of Lab Operations, and a key employee in the Company. This shows that the Wistar program is working, and we are thrilled to see a past graduate mentor future interns from within the program.”

Wistar’s BTT Program expansion is currently funded by a PAsmart Grant and a grant from the National Science Foundation. Kristy Shuda McGuire, Ph.D., Wistar’s Dean of Biomedical Studies and BTT Program lead, comments, “The support we have received at the local, state, and federal level shows their belief in this Wistar program of training strong biomedical science technicians for this growing Philadelphia life science ecosystem. We are committed to providing industry training to students to propel our strong science and innovative research community forward.”

In addition to the BTT Program expansion, Wistar will also grow the Biomedical Research Technician (BRT) Apprenticeship and magnify the reach of educational opportunities for all stages of the STEM pipeline across the region – incorporating emerging talent, academic institutions, and life science businesses into an impactful network of career opportunity.

Distinguished Lectures in Cancer Research Series: Insights Into How to Prevent Metastasis From Modeling the Biology of Disseminated Cancer Cell Dormancy

Scientific Seminar
Tuesday, May 10, 2022

The Distinguished Lectures in Cancer Research series is the flagship seminar series of the Ellen and Ronald Caplan Cancer Center and features national and international leaders in basic and translational cancer research. Recent speakers (2020-2021) included Paul Mischel, Mark Yarchoan, Maria Blasco, Job Dekker, Nicholas Proudfoot, Moshe Oren, and Judith Varner, among others.

This seminar series is hosted in either Caplan or Grossman Auditorium on Tuesdays from 12:00 – 1:00pm and is targeted to graduate and undergraduate students, staff, faculty, and anyone interested in cancer research.

If interested in attending or if you have any questions, please email Deborah Johnson at djohnson@wistar.org.

Speaker

Julio A. Aguirre-Ghiso, Ph.D.
Albert Einstein College of Medicine
Insights Into How to Prevent Metastasis From Modeling the Biology of Disseminated Cancer Cell Dormancy
Faculty Host: Maureen Murphy, Ph.D. and Jessie Villanueva, Ph.

The Wistar Institute
Caplan Auditorium
3601 Spruce Street
Philadelphia, PA, 19104

Continue reading

26th Annual Jonathan Lax Award Lecture 

Special Event
Tuesday, June. 28, 2022

Featuring Mike McCune, M.D., Ph.D., Head, HIV Frontiers, Biotechnology Accelerator, Bill & Melinda Gates Foundation

Keynote Address: Bringing Safe and Effective “Curative” Interventions for HIV and Sickle Cell Disease to Resource-limited Parts of the World

The Lax Lecture is a public lecture hosted by The Wistar Institute where leading international HIV scientists interact with local researchers, clinicians, and patient advocates. This year, we are pleased to partner with international sponsors. Following the Lecture, a panel of global HIV cure community advocates will discuss the question, “What does a cure for HIV mean to me?”.

About Jonathan Lax:

Now in its 26th year, the Jonathan Lax Award Lecture honors the memory of Jonathan Lax, a community leader who made significant contributions to civil rights, gay rights, and HIV activism/therapy. Mr. Lax was a businessman, inventor, teacher, and one of the best-known AIDS activists in Philadelphia’s clinical research network, working with many groups to try and speed the drug approval process. Mr. Lax was involved in accelerating access to new drugs and offered himself as a participant in studies of new AIDS therapies that—with his help—had been brought to Philadelphia. He facilitated dozens of seminars focused on improving our understanding of how to live with AIDS, and he was the co-author of the well-respected handbook HIV Adult Standard of Care. Perhaps most importantly, he was an advisor to those infected with the HIV virus. Mr. Lax was particularly proud of his role as an instructor for the Department of Preventive Medicine and Public Health at Hahnemann University and the AIDS Education Training Center of Pennsylvania.

Mr. Lax died in January of 1996. In the year before his death, he established the Lax Scholarship Fund for Gay Men, a unique nationwide scholarship program. He lived to see the first scholarships given to exceptional young gay scholars. He left funds to start a clinic, today the Jonathan Lax Center at Philadelphia FIGHT, which is the largest provider of AIDS care in Philadelphia and offers treatment independent of a patient’s ability to pay for services.

SPONSORS
  • Beat-HIV

  • Botswana-UPenn

  • CanCURE

  • CFAR

  • EU2CURE

  • FAIS

  • GGTI

  • HCAAP

  • IndianIummunologySocirty

  • JABASA logo

  • PhiladelphiaFIGHT

  • PhiladelphiaFoundation

  • Sadi

  • TAG_final

  • Wistar

Speakers & Panelists
  • Mike McCune, M.D., Ph.D.

    Keynote Speaker

    Head, HIV Frontiers, Biotechnology Accelerator
    Bill & Melinda Gates Foundation

  • Luis J. Montaner, D.V.M., D.Phil.

    Speaker

    Herbert Kean, M.D., Family Endowed Chair Professor, Vice President of Scientific Operations
    The Wistar Institute

  • Jane Shull

    Speaker

    Executive Director
    Philadelphia FIGHT

  • Philister Adhiambo

    Panelist

    Community Liaison Officer and HIV Cure Advocate
    Kenya

  • Michael Louella

    Panelist

    Community Engagement Project Manager
    USA

  • Moses “Supercharger” Nsubuga

    Panelist

    HIV Outreach and HIV Cure Research Advocate
    Uganda

Agenda

9:30 AM
Welcome Remarks and Global Focus
Luis J. Montaner, D.V.M., D.Phil.
The Wistar Institute

9:40 AM
Optimistic Music Video
Moses “Supercharger”
JABASA

9:50 AM
Awards Lecture History
Jane Shull
Philadelphia FIGHT

10:05 AM
Keynote Address: “Bringing Safe and Effective “Curative” Interventions for HIV and Sickle
Cell Disease to Resource-limited Parts of the World.”
Mike McCune, M.D., Ph.D.
HIV Frontiers, Biotechnology Accelerator, Bill & Melinda Gates Foundation

10:50 AM
Global Community Panel Discussion Moderated by Luis Montaner – What Does a Cure
Mean to You?

  • Philister Adhiambo – Community Liaison Officer and HIV Cure Advocate, Kenya
  • Michael Louella – Community Engagement Project Manager, USA
  • Moses “Supercharger” – HIV Outreach and HIV Cure Research Advocate, Uganda

11:30 AM
Adjourn

Continue reading